Stock Analysis

What Should We Expect From Clovis Oncology, Inc.'s (NASDAQ:CLVS) Earnings Over The Next Few Years?

OTCPK:CLVS.Q
Source: Shutterstock

Clovis Oncology, Inc.'s (NASDAQ:CLVS) latest earnings announcement in December 2018 showed that losses became smaller relative to the prior year's level - great news for investors Below, I've presented key growth figures on how market analysts perceive Clovis Oncology's earnings growth outlook over the next few years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying drivers of earnings.

View our latest analysis for Clovis Oncology

Analysts' outlook for next year seems relatively subdued, with earnings continuing to flop around in the negative territory, reaching -US$390.1m in 2020. Moreover, earnings are expected to fall further in the following year, declining to -US$375.6m in 2021 and -US$267.3m in 2022.

NasdaqGS:CLVS Past and Future Earnings, March 7th 2019
NasdaqGS:CLVS Past and Future Earnings, March 7th 2019

Although it is helpful to understand the growth rate year by year relative to today’s value, it may be more beneficial to estimate the rate at which the earnings are growing on average every year. The pro of this approach is that it removes the impact of near term flucuations and accounts for the overarching direction of Clovis Oncology's earnings trajectory over time, which may be more relevant for long term investors. To calculate this rate, I've inserted a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is 27%. This means, we can presume Clovis Oncology will grow its earnings by 27% every year for the next few years.

Advertisement

Next Steps:

For Clovis Oncology, there are three relevant aspects you should further research:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does CLVS's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of CLVS? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About OTCPK:CLVS.Q

Clovis Oncology

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.

Slightly overvalued with weak fundamentals.

Advertisement